or Try an Advanced Search...

    Liver Disease Stocks List

    Symbol Grade Name % Change
    NTLA F Intellia Therapeutics, Inc. 1.93
    GRI F GRI Bio, Inc. -4.86
    HEPA F Hepion Pharmaceuticals, Inc. 1.77
    ALGS F Aligos Therapeutics, Inc. -0.37
    TARA F ArTara Therapeutics, Inc. 1.70
    MIRM D Mirum Pharmaceuticals, Inc. -0.88
    BFRG D Bullfrog AI Holdings, Inc -0.37
    GYRE D Gyre Therapeutics, Inc. 9.96
    ALNY C Alnylam Pharmaceuticals, Inc. -0.57
    GALT C Galectin Therapeutics Inc. 3.68
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Health Information Services
    Related Stock Lists: Medicine Hepatitis Non Alcoholic Fatty Liver Disease Steatohepatitis Biopharmaceutical Hepatitis B Alcohol Amyloid Amyloidosis Antitrypsin Deficiency Biotechnology Chronic Liver Diseases Fatty Liver Disease Hepatology IBD 50 Immune System Lipid Liver Fibrosis Transthyretin Acid

    Related ETFs - A few ETFs which own one or more of the above listed Liver Disease stocks.

    Symbol Grade Name Weight
    GNOM F Global X Genomics & Biotechnology ETF 10.37
    HRTS D Tema Cardiovascular and Metabolic ETF 5.3
    PBE D PowerShares Dynamic Biotech & Genome 5.03
    BBP C BioShares Biotechnology Products Fund 4.85
    ARKG F ARK Genomic Revolution Multi-Sector ETF 4.76
    View all Liver Disease ETFs...
    Compare ETFs
    Compare BBP to ARKG Compare GNOM to ARKG Compare PBE to ARKG

        Liver Disease Stocks Recent News

        Date Stock Title
        Oct 4 MIRM Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish
        Oct 3 NTLA Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 10% this week, taking three-year losses to 86%
        Oct 3 MIRM Exploring High Growth Tech Stocks In The US October 2024
        Oct 3 ALNY Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is Expected To Breakeven In The Near Future
        Oct 2 ALNY Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
        Oct 1 GYRE Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
        Oct 1 ALNY Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
        Oct 1 ALNY Not Holding Alnylam Pharmaceuticals (ALNY) Hurt Fidelity Growth Strategies Fund’s Performance
        Oct 1 NTLA Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
        Sep 30 GRI GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions
        Sep 30 ALGS Aligos Therapeutics to Present at Investor Conferences in October
        Sep 30 GALT Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
        Sep 29 ALNY Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
        Sep 29 NTLA 2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
        Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Health Information Services
        Related Stock Lists: Medicine Hepatitis Non Alcoholic Fatty Liver Disease Steatohepatitis Biopharmaceutical Hepatitis B Alcohol Amyloid Amyloidosis Antitrypsin Deficiency Biotechnology Chronic Liver Diseases Fatty Liver Disease Hepatology IBD 50 Immune System Lipid Liver Fibrosis Transthyretin Acid
        Liver Disease

        Liver disease (also called hepatic disease) is a type of damage to or disease of the liver. Whenever the course of the problem lasts long, chronic liver disease ensues.

        More about Liver Disease
        Browse All Tags